Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Injectable Ibuprofen Approved for Treating Pain & Fever NASHVILLE, Tenn., Oct. 1 , 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced that its ibuprofen injection product, has received regulatory approval in Mexico. The approval follows Cumberland's partnership with PiSA Farmaceutica, which includes exclusive supply and distribution rights for the ibuprofen product in the Mexican market. PiSA is a well-established Mexican pharmaceutical firm with a leading injectable business in that country. Under the agreem
Vibativ® treats patients with pneumonia and serious skin infections NASHVILLE, Tenn. and RIYADH, Saudi Arabia, Sept. 29, 2025 /PRNewswire/ -- Specialty pharmaceutical companies Tabuk Pharmaceutical Manufacturing Company a fully owned subsidiary of Astra Industrial Group and a leading pharmaceutical company in the Middle East and Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the launch of Cumberland's Vibativ® (telavancin) injection in Saudi Arabia. The announcement follows an agreement between the companies providing Tabuk
Sitryx appoints Adam Mostafa as Chief Financial Officer Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership Oxford, UK and Boston, MA – 8 September 2025 – Sitryx Therapeutics ("the Company"), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announces the appointment of Adam Mostafa as Chief Financial Officer (CFO), effective today. With over 25 years of experience, Adam is a seasoned biotech executive and financial leader. He joins Sitryx with a distinguished background spanning across biotech and healthcare financial
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
10-Q - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
8-K - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
10-Q - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
Sitryx appoints Adam Mostafa as Chief Financial Officer Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership Oxford, UK and Boston, MA – 8 September 2025 – Sitryx Therapeutics ("the Company"), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announces the appointment of Adam Mostafa as Chief Financial Officer (CFO), effective today. With over 25 years of experience, Adam is a seasoned biotech executive and financial leader. He joins Sitryx with a distinguished background spanning across biotech and healthcare financial
NASHVILLE, Tenn., July 19, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that Martin Brown Jr. has joined the company's Board of Directors. Brown previously served for 10 years on the Board of directors of Brown-Forman Corporation, a large American wine and spirits company listed on the New York Stock Exchange. The brands in Brown-Forman's portfolio include Jack Daniel's and Woodford Reserve whiskeys, Benriach scotch, Herradura tequila and Finlandia vodka. Brown is an attorney at Adams and Reese LLP, a
Injectable Ibuprofen Approved for Treating Pain & Fever NASHVILLE, Tenn., Oct. 1 , 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced that its ibuprofen injection product, has received regulatory approval in Mexico. The approval follows Cumberland's partnership with PiSA Farmaceutica, which includes exclusive supply and distribution rights for the ibuprofen product in the Mexican market. PiSA is a well-established Mexican pharmaceutical firm with a leading injectable business in that country. Under the agreem
Vibativ® treats patients with pneumonia and serious skin infections NASHVILLE, Tenn. and RIYADH, Saudi Arabia, Sept. 29, 2025 /PRNewswire/ -- Specialty pharmaceutical companies Tabuk Pharmaceutical Manufacturing Company a fully owned subsidiary of Astra Industrial Group and a leading pharmaceutical company in the Middle East and Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the launch of Cumberland's Vibativ® (telavancin) injection in Saudi Arabia. The announcement follows an agreement between the companies providing Tabuk
NASHVILLE, Tenn., Aug. 5, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $10.8 million during the second quarter of 2025, a 10% increase over the prior year period. Year-to-date revenues for the first six months of the year totaled $22.6 million, representing an increase of 23% over the first half of 2024. Cumberland ended the quarter with approximately $68 million in total assets, $40 million in liabilities and $28 milli
SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)
SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)
SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)